Refine
Year of publication
Document Type
- Conference Proceeding (756)
- Lecture (534)
- Article (425)
- Part of a Book (38)
- Book (26)
- Doctoral Thesis (10)
- Report (8)
- Master's Thesis (1)
Language
- English (1798) (remove)
Keywords
- Education (120)
- Embedded Systems (105)
- Teaching (78)
- Tissue Engineering (47)
- Power Conversion (43)
- Robotics (41)
- eHealth (40)
- Computer Science (39)
- Security (39)
- Tunnel (37)
Department
- Department Computer Science (512)
- Department Electronic Engineering (467)
- Department Life Science Engineering (394)
- Department Industrial Engineering (235)
- Publiziert vor FH-Zugehörigkeit (118)
- Department Angewandte Mathematik und Physik (90)
- Department Entrepreneurship & Communications (76)
- Sonstiges (2)
Automatic classification of a full-thickness macular hole in optical coherence tomography images
(2023)
A Turbulent Context
(2023)
Interface with WP123200
(2023)
Requirements from WP123200
(2022)
Local inflammation plays a pivotal role in the process of secondary damage after spinal cord injury. We recently reported that acute intravenous application of extracellular vesicles (EVs) secreted by human umbilical cord mesenchymal stromal cells dampens the induction of inflammatory processes following traumatic spinal cord injury. However, systemic application of EVs is associated with delayed delivery to the site of injury and the necessity for high doses to reach therapeutic levels locally. To resolve these two constraints, we injected EVs directly at the lesion site acutely after spinal cord injury. We report here that intralesional application of EVs resulted in a more robust improvement of motor recovery, assessed with the BBB score and sub-score, as compared to the intravenous delivery. Moreover, the intralesional application was more potent in reducing inflammation and scarring after spinal cord injury than intravenous administration. Hence, the development of EV-based therapy for spinal cord injury should aim at an early application of vesicles close to the lesion.
Bone grafts can be engineered by differentiating human mesenchymal stromal cells (MSCs) via the endochondral and intramembranous ossification pathways. We evaluated the effects of each pathway on the properties of engineered bone grafts and their capacity to drive bone regeneration. Bone-marrow-derived MSCs were differentiated on silk scaffolds into either hypertrophic chondrocytes (hyper) or osteoblasts (osteo) over 5 weeks of in vitro cultivation, and were implanted subcutaneously for 12 weeks. The pathways' constructs were evaluated over time with respect to gene expression, composition, histomorphology, microstructure, vascularization and biomechanics. Hypertrophic chondrocytes expressed higher levels of osteogenic genes and deposited significantly more bone mineral and proteins than the osteoblasts. Before implantation, the mineral in the hyper group was less mature than that in the osteo group. Following 12 weeks of implantation, the hyper group had increased mineral density but a similar overall mineral composition compared with the osteo group. The hyper group also displayed significantly more blood vessel infiltration than the osteo group. Both groups contained M2 macrophages, indicating bone regeneration. These data suggest that, similar to the body's repair processes, endochondral pathway might be more advantageous when regenerating large defects, whereas intramembranous ossification could be utilized to guide the tissue formation pattern with a scaffold architecture.